Limits...
Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G - Br. J. Cancer (2002)

Bottom Line: The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival.Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy.In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, I-20141, Milano, Italy.

Show MeSH

Related in: MedlinePlus

MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375191&req=5

fig2: MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.

Mentions: Figure 2Figure 2


Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G - Br. J. Cancer (2002)

MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375191&req=5

fig2: MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
Mentions: Figure 2Figure 2

Bottom Line: The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival.Nineteen patients (treated) received adjuvant treatment with radioimmunotherapy.In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, I-20141, Milano, Italy.

Show MeSH
Related in: MedlinePlus